Kosalaraksa P, Kavlick M F, Maroun V, Le R, Mitsuya H
Experimental Retrovirology Section, Department of Developmental Therapeutics, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Virol. 1999 Jul;73(7):5356-63. doi: 10.1128/JVI.73.7.5356-5363.1999.
We examined whether human immunodeficiency virus type 1 (HIV-1) fitness was altered upon the acquisition of a set or subset of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene, which confers resistance to multiple dideoxynucleosides (MDR), as well as the zidovudine resistance-associated mutation T215Y, using a competitive HIV-1 replication assay in a setting of an HXB2D genetic background. Target H9 cells were exposed to a 50:50 mixture of paired infectious molecular clones, and HIV-1 in the culture supernatant was transmitted to new cultures every 7 to 10 days. The polymerase-encoding region of the virus was sequenced at various time points, and the relative proportion of the two viral populations was determined. In the absence of drugs, the comparative order for replicative fitness was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > wild-type HIV-1 (HIV-1wt) > HIV-175/77/116/151 > HIV-1151/215 > HIV-1215. In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-175/77/116/151 > HIV-1151 > HIV-1215. HIV-1215S(TCC), a putative intermediate infectious clone for HIV-1215, replicated comparably to HIV-1wt, while two putative intermediates for HIV-1151 [HIV-1151L(CTG) and HIV-1151K(AAG)] replicated much less efficiently than HIV-1wt and HIV-1151, suggesting that for HIV-1151 to develop, two base substitutions are likely to occur concurrently or within a short interval. These data may illustrate the molecular basis by which HIV-1151 emerges much less frequently than HIV-1215. The present data also demonstrate that several MDR HIV-1 variants are more fit than HIV-1wt in the absence of drugs and that resistance-associated mutations and drug pressure are critical variates for HIV-1 fitness.
我们使用竞争性HIV-1复制试验,在HXB2D遗传背景下,研究了1型人类免疫缺陷病毒(HIV-1)在获得pol基因中的一组或一个子集的五个突变(A62V、V75I、F77L、F116Y和Q151M)后其适应性是否发生改变,这些突变赋予了对多种双脱氧核苷(MDR)的抗性以及齐多夫定抗性相关突变T215Y。将靶细胞H9暴露于成对感染性分子克隆的50:50混合物中,并且每7至10天将培养上清液中的HIV-1传播至新的培养物中。在不同时间点对病毒的聚合酶编码区进行测序,并确定两个病毒群体的相对比例。在无药物情况下,复制适应性的比较顺序为:HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > 野生型HIV-1(HIV-1wt)> HIV-175/77/116/151 > HIV-1151/215 > HIV-1215。HIV-1215S(TCC)是HIV-1215的一个假定中间感染性克隆,其复制效率与HIV-1wt相当,而HIV-1151的两个假定中间体[HIV-1151L(CTG)和HIV-11五万一千(AAG)]的复制效率远低于HIV-1wt和HIV-1151,表明对于HIV-1151的产生,两个碱基替换可能同时发生或在短时间间隔内发生。这些数据可能说明了HIV-1151出现频率远低于HIV-1215的分子基础。目前的数据还表明,几种MDR HIV-1变体在无药物情况下比HIV-1wt更具适应性,并且抗性相关突变和药物压力是HIV-1适应性的关键变量。